Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses RNAi Patents to Invitrogen, Cell Signaling Technology, Cenix

NEW YORK, Jan. 13 (GenomeWeb News) - Alnylam Pharmaceuticals has licensed RNA interference patents to Invitrogen, Cell Signaling Technology, and Cenix Bioscience, the company said today.

 

Invitrogen, headquartered in Carlsbad, Calif., has obtained a license to provide research products and services under a patent family owned by Alnylam that covers the use of short double-stranded RNAs to mediate RNAi and that includes European patent 1 144 623.

 

Cell Signaling Technology, located in Beverly, Mass., has licensed one RNAi patent to provide research products. Following an initial payment, the company will pay Alnylam annual fees and royalties on product sales.

 

Cenix BioScience, of Dresden, Germany, has licensed one RNAi patent to market its RNAi research services. It will pay Alnylam annual fees and royalties on the services it provides. In addition, Cenix will provide Alnylam with its expertise in designing and testing small interfering RNAs.

 

The licenses were granted by Ribopharma of Kulmbach, Germany, one of Alnylam's two operating units.

 

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.